- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
AML treatment market to reach $932.6 million by 2024
9 December 2015 • Author: Victoria White
The treatment market for acute myeloid leukaemia (AML) will rapidly expand in value from $342.7 million in 2014 to reach $932.6 million by 2024, says research and consulting firm GlobalData.
According to the company’s latest report, OpportunityAnalyzer: Acute Myeloid Leukaemia (AML) – Opportunity Analysis and Forecasts to 2024, this huge increase, which will occur across the seven major markets of the US, Japan, the UK, Spain, Italy, France and Germany, will primarily be due to the launch of new therapies for AML patients with high unmet needs.
Sorcha Cassidy, Ph.D., GlobalData’s Analyst covering Oncology and Haematology, says the greatest unmet need in the market is improving the overall survival rate of elderly AML patients which, compared to that of younger favorable-risk patients, is substantially lower.
Cassidy comments: “Fulfilling this unmet need is a safe route to regulatory approval and commercial success. In this way, one of the major drivers of AML treatment sales across the seven major markets will be the launch of premium-priced therapies for elderly AML patients, such as Ambit’s quizartinib.
“Other growth drivers will include an increasing branded drug treatment rate, a rising number of refractory/relapsed cases of acute myeloid leukaemia across all age groups, and a growing desire to develop immunotherapies to treat acute myeloid leukaemia patients.”
Vyxeos to be the branded AML treatment market leader
GlobalData’s report also states that by 2024, the branded AML market leader will be Vyxeos, with estimated total sales of $131 million in the US and five European countries.
Cassidy concludes: “GlobalData does not believe the efficacy of Vyxeos will be exceptional, but it will be an improvement on the current standard of care.
“However, the drug’s premium price, the sizeable population of elderly AML patients, and the absence of immediate competition will drive higher sales from Vyxeos than any other pipeline or marketed product.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics